Dr. Susan Knox

• 
  pharminfo.8media.org/pubs/msb/radioimmun.html - [Cached Version]
  Published on: 10/6/2008    Last Visited: 12/14/2007  

  "The main reason for the greater effectiveness in these diseases is that leukemias and lymphomas are very radiosensitive," explains Dr. Susan Knox, radiation oncologist in the department of radiation oncology at Stanford University Medical Center."Leukemia and lymphoma cells are less able to repair radiation-induced damage than are cells of solid tumors."
  
  With support from the NCRR's General Clinical Research Centers (GCRC) Program, Dr. Knox is testing the effects of yttrium-90 combined with a monoclonal antibody that binds to B-cell lymphoma cells.
  
  In a recent study of 18 patients, Dr. Knox saw 6 complete and 7 partial remissions that continued from 3 to more than 29 months.This study also helped Dr. Knox's team to determine the maximal dose of yttrium-90-labeled antibody that was tolerated by the patients information the researchers will apply in multicenter trials that are set to begin in late 1995 or early 1996.
  ...
  "Some antibodies themselves can kill cells," says Dr. Knox, "but in general, most of the cancer cell killing is due to radiation."
  ...
  Knox, S. J., Radioimmunotherapy of non-Hodgkin's lymphoma.Seminars in Radiation Oncology 5:331-341, 1995.

• 
  www.interwest.com/team/knox.html - [Cached Version]
  Published on: 3/3/2007    Last Visited: 3/3/2007  

  Susan J. Knox, M.D., Ph.D.InterWest Partners - Investing in Information Technology & Life Sciences
  ...
  Susan J. Knox, Ph.D., M.D.ConsultantLife Sciences
  
  Susan Knox, Ph.D., M.D., is a consultant with InterWest Partners Life Sciences¹ team and currently serves as an Associate Professor at Stanford University School of Medicine in the Department of Radiation Oncology.Knox brings more than 20 years of experience working in the medical field, focusing on Radiation Oncology and transitional medicine.Knox has her BA from University of California, Berkeley; PhD from University of California, Davis; and MD from Stanford University School of Medicine.
  
  At the beginning of her career, Knox served as a Medical Intern at UC Davis Medical Center and was a Post-Doctoral Fellow at Stanford University Hospital in the Departments of Medical and Radiation Oncology.She served her residency at Stanford University Hospital in the Department of Radiation Oncology.

• 
  www.microarray.org/sfgf/initRegistration.do - [Cached Version]
  Published on: 10/6/2008    Last Visited: 2/25/2008  

  Susan Knox Stanford

• 
  www.interwest.com/team/lifesciences.html - [Cached Version]
  Published on: 3/3/2007    Last Visited: 3/3/2007  

  Susan J. Knox, M.D., Ph.D.Consultant

• 
  www.larad.org/meetings/MidWinter/2008/MWO/lMidwinter%20 - [Cached Version]
  Published on: 10/6/2008    Last Visited: 9/7/2007  

  Susan J. Knox, MD, PhD

• 
  CEO Of EpiCor Joins Interwest as Venture Partner; Med... - [Cached Version]
  Published on: 1/8/2001    Last Visited: 1/8/2001  

  In addition, InterWest will add Stanford radiation oncologist Susan Knox, M.D., Ph.D. and Genentech molecular biologist Larry Lasky, Ph.D. as team consultants.

• 
  Coulter Pharmaceutical - [Cached Version]
  Published on: 10/20/1997    Last Visited: 9/13/2000  

  The preliminary data were generated from 15 patients of a planned 78-patient randomized, controlled Phase II clinical trial and were presented by Susan Knox, M.D., Ph.D., associate professor, Radiation Oncology at Stanford University Medical Center and a principal investigator for the clinical trial.
  
  The trial is being conducted in low-grade, non-Hodgkin's lymphoma patients with chemotherapy refractory NHL who have progressed within one year after completing their last chemotherapy regimen.Patients are randomized 1 : 1 to receive either Bexxar therapy or the unlabeled monoclonal antibody specific for the CD20 antigen found on NHL cells.
  
  Dr. Knox reported that 75 percent (six of eight) of the patients randomized to the Bexxar arm responded to the therapy, compared to only 43 percent (three of seven) of patients who responded to the unlabeled antibody.Two of the patients in the Bexxar arm experienced a complete remission of their disease while only one patient in the unlabeled antibody arm achieved a complete remission.
  
  While follow-up is limited in this preliminary report, the longest time to progression for Bexxar-treated patients was nine months (ongoing) compared to five months with that for unlabeled antibody-treated patients.Follow-up evaluation will be conducted to confirm all responses.Both treatments were well-tolerated with the only significant toxicity being temporary and reversible myelosuppression.
  
  ...
  Dr. Knox commented, The results in the unlabeled antibody arm are fairly consistent with previous results reported with the use of unmodified anti-CD20 antibodies for the treatment of non-Hodgkin's lymphoma.Though the trial is still ongoing, the results do indicate a trend toward more durable complete remissions and a higher overall response rate using radiolabeled Bexxar in treating non-Hodgkin's lymphoma.For this reason, the trial allows patients randomized to the unlabeled antibody arm to crossover to the Bexxar arm following disease progression.Data from these crossover patients are still being generated..
  
  Bexxar, which is an antibody radiolabeled with iodine-131 (I131), attaches to a protein found only on the surface of B-cells, both non-Hodgkin's lymphoma B-cells and some normal B-cells.Through this targeted approach, the tumor cells receive a higher dose of the therapeutic radiation from Bexxar relative to normal tissues.

• 
  DIATOS SA - Advisors - [Cached Version]
  Published on: 9/15/2007    Last Visited: 9/15/2007  

  Dr Susan Knox, MD, PhDAssociate Professor Radiation Oncology, Stanford University Medical Center, USA.

• 
  ESE - [Cached Version]
  Published on: 3/23/2006    Last Visited: 8/27/2007  

  Ms. Susan Knox - Science

• 
  Editorial Board - [Cached Version]
  Published on: 8/7/2001    Last Visited: 7/28/2004  

  Susan J. Knox, MD, PhDStanford, CA

Page:  1 2 3